Abstract
Theranostic medicine is relatively a new term that describes integration of diagnostic and therapeutic functions within the same platform of pharmaceuticals. Such a design may in principle permit the molecular diagnosis, targeted therapy, and simultaneous monitoring and treatment necessary to achieve personalized medicine for cancer. Theranostic radiopharmaceuticals, for instance, carry the properties of both diagnostic radioimaging and radioimmunotherapy (RIT). As nuclear imaging techniques such as positron emission tomography (PET) or single photon emission computed tomography (SPECT) have excellent sensitivity and can provide biochemical information on pathological conditions, much effort has been made in order to accomplish a more effective and powerful theranostic combination. Some recent examples include SPECT-therapy, PET-therapy, and therapy-therapy. In particular, the combined therapy-therapy method is the result of realization that RIT relying on a single radioisotope has an inherent limitation for practical cancer treatment. Thus the success of theranostic nuclear medicine depends on a proper choice of different radioisotopes that will lead to a perfect couple. This pair of radioisotopes is called matched-pair radioisotopes. The structural motif for radiopharmaceuticals based on matched-pair consists of a bifunctional chelator (BFCA) and a biologically active molecule (BAM). This review will focus on recent advances in radiopharmaceutical application of matched-pair radiometals in clinics as well as preclinics.
Keywords: Theranostic, radioimaging, radioimmunotherapy, bifunctional chelator, matched-pair radiometals
Current Topics in Medicinal Chemistry
Title:Recent Advances in Radiopharmaceutical Application of Matched-Pair Radiometals
Volume: 13 Issue: 4
Author(s): Ji-Ae Park and Jung Young Kim
Affiliation:
Keywords: Theranostic, radioimaging, radioimmunotherapy, bifunctional chelator, matched-pair radiometals
Abstract: Theranostic medicine is relatively a new term that describes integration of diagnostic and therapeutic functions within the same platform of pharmaceuticals. Such a design may in principle permit the molecular diagnosis, targeted therapy, and simultaneous monitoring and treatment necessary to achieve personalized medicine for cancer. Theranostic radiopharmaceuticals, for instance, carry the properties of both diagnostic radioimaging and radioimmunotherapy (RIT). As nuclear imaging techniques such as positron emission tomography (PET) or single photon emission computed tomography (SPECT) have excellent sensitivity and can provide biochemical information on pathological conditions, much effort has been made in order to accomplish a more effective and powerful theranostic combination. Some recent examples include SPECT-therapy, PET-therapy, and therapy-therapy. In particular, the combined therapy-therapy method is the result of realization that RIT relying on a single radioisotope has an inherent limitation for practical cancer treatment. Thus the success of theranostic nuclear medicine depends on a proper choice of different radioisotopes that will lead to a perfect couple. This pair of radioisotopes is called matched-pair radioisotopes. The structural motif for radiopharmaceuticals based on matched-pair consists of a bifunctional chelator (BFCA) and a biologically active molecule (BAM). This review will focus on recent advances in radiopharmaceutical application of matched-pair radiometals in clinics as well as preclinics.
Export Options
About this article
Cite this article as:
Park Ji-Ae and Kim Jung Young, Recent Advances in Radiopharmaceutical Application of Matched-Pair Radiometals, Current Topics in Medicinal Chemistry 2013; 13 (4) . https://dx.doi.org/10.2174/1568026611313040006
DOI https://dx.doi.org/10.2174/1568026611313040006 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure-Function Relationships in the Interaction Between the Urokinase- Type Plasminogen Activator and Its Receptor
Current Pharmaceutical Design Cancer and Cyclooxygenase-2 (COX-2) Inhibition
Current Pharmaceutical Design Heat Shock Protein 90 Inhibitors as Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery The Role of Pemetrexed in Lung Adenocarcinoma, Mixed Subtype with Bronchioloalveolar Carcinoma Features
Current Drug Targets The Functions of Histone Modification Enzymes in Cancer
Current Protein & Peptide Science Biological Interfacial Engineering for Metastatic Cancer Diagnosis and Intervention
Current Medicinal Chemistry Cancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls
Current Pharmaceutical Biotechnology Expression Microarray Proteomics and the Search for Cancer Biomarkers
Current Genomics Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
Current Cancer Drug Targets Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry Literature Review: Use of Family History for Primary Paediatric Care as the Next Step Towards use of Genomics in Healthcare
Current Pediatric Reviews Chemoprevention of Colorectal Cancer: Ready for Routine Use?
Current Topics in Medicinal Chemistry Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets The Use of Nimesulide and Its Analogues in Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenomics in a Global World: A Roadmap for Australia, Prospects and Challenges
Current Pharmacogenomics and Personalized Medicine Quercetin and MicroRNA Interplay in Apoptosis Regulation in Ovarian Cancer
Current Pharmaceutical Design MUC Glycoproteins: Potential Biomarkers and Molecular Targets for Cancer Therapy
Current Cancer Drug Targets Peptides Targeting Angiogenesis Related Growth Factor Receptors
Current Pharmaceutical Design Ligand-Targeted Liposomes for Cancer Treatment
Current Drug Delivery